Authors : Sneha Jin J. D.; Dr. A. Pandi Selvi

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/55aatne4

Scribd : https://tinyurl.com/ycy3mbtm

DOI : https://doi.org/10.38124/ijisrt/25aug1235

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : A major global health burden, non-alcoholic fatty liver disease (NAFLD) is strongly linked to obesity, metabolic syndrome, and sedentary lifestyles. Since there are now no FDA-approved drugs on the market, there is a growing need for safe, natural, and efficient medicinal substitutes. This review investigates how phytoconstituents produced from plants can help manage NAFLD by focusing on the AMP-activated protein kinase (AMPK) pathway, which is a key regulator of energy and lipid metabolism. The mechanisms involving the AMPK-ACC-PPARα, AMPK/Nrf2, Sirt1/AMPK, AMPK/mTOR/ULK1, and AdipoR1-AMPK signalling axes are described regarding important phytochemicals such as gallic acid, plantamajoside, kaempferol, methylsulfonylmethane, and atractylenolide III. These substances show promise in reducing oxidative stress, promoting fatty acid oxidation, inhibiting de-novo lipogenesis, restoring autophagy, and regulating inflammation. According to the results, phytoconstituents have the potential to be effective multi-targeted agents in the management and prevention of NAFLD. To convert these discoveries into successful treatment plans, more research on clinical validation, bioavailability, and formulation development is required.

Keywords : Non-Alcoholic Fatty Liver Disease (NAFLD), AMP-Activated Protein Kinase (AMPK), Phytoconstituents, Lipid Metabolism, Oxidative Stress, Natural Products.

References :

1. Yan BF, Pan LF, Quan YF, Sha Q, Zhang JZ, Zhang YF, Zhou LB, Qian XL, Gu XM, Li FT, Wang T. Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway. World Journal of Gastroenterology. 2023 Aug 21;29(31):4744.
2. Balbuena E, Cheng J, Eroglu A. Carotenoids in orange carrots mitigate non-alcoholic fatty liver disease progression. Frontiers in Nutrition. 2022 Sep 26;9:987103.
3. Panahi Y, Kianpour P, Mohtashami R, Soflaei SS, Sahebkar A. Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: a clinical study. Journal of Asian natural products research. 2019 Aug 3.
4. Zhou DD, Mao QQ, Li BY, Saimaiti A, Huang SY, Xiong RG, Shang A, Luo M, Li HY, Gan RY, Li HB. Effects of different green teas on obesity and non-alcoholic fatty liver disease induced by a high-fat diet in mice. Frontiers in Nutrition. 2022 Jun 24;9:929210.
5. Auth PA, da Silva GR, Amaral EC, Bortoli VF, Manzano MI, de Souza LM, Lovato EC, Ribeiro-Paes JT, Gasparotto Junior A, Livero FA. Croton urucurana Baill. ameliorates metabolic associated fatty liver disease in rats. Frontiers in Pharmacology. 2022 May 20;13:886122.
6. Lee MR, Yang HJ, Park KI, Ma JY. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice. Phytomedicine. 2019 Mar 1;55:14-22.
7. Yang K, Zhang L, Liao P, Xiao Z, Zhang F, Sindaye D, Xin Z, Tan C, Deng J, Yin Y, Deng B. Impact of gallic acid on gut health: focus on the gut microbiome, immune response, and mechanisms of action. Frontiers in immunology. 2020 Sep 16;11:580208.
8. Cedo L, Castell-Auvi A, Pallares V, Macia A, Blay M, Ardevol A, Motilva MJ, Pinent M. Gallic acid is an active component for the anticarcinogenic action of grape seed procyanidins in pancreatic cancer cells. Nutrition and cancer. 2014 Jan 1;66(1):88-96.
9. Ferruzzi MG, Lobo JK, Janle EM, Cooper B, Simon JE, Wu QL, Welch C, Ho L, Weaver C, Pasinetti GM. Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. Journal of Alzheimer’s Disease. 2009 Jul 29;18(1):113-24.
10. Scoccia J, Perretti MD, Monzón DM, Crisóstomo FP, Martín VS, Carrillo R. Sustainable oxidations with air mediated by gallic acid: potential applicability in the reutilization of grape pomace. Green Chemistry. 2016;18(9):2647-50.
11. Wang C, Li W. Optimization technology of the LHS-1 strain for degrading gallnut water extract and appraisal of benzene ring derivatives from fermented gallnut water extract pyrolysis by Py-GC/MS. Molecules. 2017 Dec 20;22(12):2253.
12. Singh M, Jha A, Kumar A, Hettiarachchy N, Rai AK, Sharma D. Influence of the solvents on the extraction of major phenolic compounds (punicalagin, ellagic acid and gallic acid) and their antioxidant activities in pomegranate aril. Journal of Food Science and Technology. 2014 Sep;51(9):2070-7.
13. Jiang H, Yu F, Qin LI, Zhang NA, Cao Q, Schwab W, Li D, Song C. Dynamic change in amino acids, catechins, alkaloids, and gallic acid in six types of tea processed from the same batch of fresh tea (Camellia sinensis L.) leaves. Journal of Food Composition and Analysis. 2019 Apr 1;77:28-38.
14. Zhang J, Zhang W, Yang L, Zhao W, Liu Z, Wang E, Wang J. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function. Phytomedicine. 2023 Jan 1;109:154589.
15. Samuelsen AB. The traditional uses, chemical constituents and biological activities of Plantago major L. A review. Journal of ethnopharmacology. 2000 Jul 1;71(1-2):1-21.
16. Li Y, Gan L, Li GQ, Deng L, Zhang X, Deng Y. Pharmacokinetics of plantamajoside and acteoside from Plantago asiatica in rats by liquid chromatography–mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2014 Feb 15;89:251-6.
17. Wen Y, Zhan Y, Tang S, Kang J, Wu R, Tang X. Mechanistic prediction of Chinese herb compound (Zhi Zhu Ma Ren Pill) in the treatment of constipation using network pharmacology and molecular docking. Natural Product Communications. 2022 Sep;17(9):1934578X221124780.
18. Wang Y, Yan D. Plantamajoside exerts antifibrosis effects in the liver by inhibiting hepatic stellate cell activation. Experimental and therapeutic medicine. 2019 Oct;18(4):2421-8.
19. Zhang L, Guo YN, Liu J, Wang LH, Wu HQ, Wang T, Deng B, Wang JY, Lu L, Chen ZX, He JQ. Plantamajoside attenuates cardiac fibrosis via inhibiting AGEs activated‐RAGE/autophagy/EndMT pathway. Phytotherapy Research. 2023 Mar;37(3):834-47.
20. Yin W, Xu J, Li C, Dai X, Wu T, Wen J. Plantamajoside inhibits the proliferation and epithelial‐to‐mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia‐inducible factor‐1α‐dependent gene expression. Cell Biology International. 2020 Aug;44(8):1616-27.
21. Zan Y, Dai Z, Liang L, Deng Y, Dong L. Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment. Drug Delivery. 2019 Jan 1;26(1):1080-91.
22. Wu JM, Zhaori G, Mei L, Ren XM, Laga AT, Deligen B. Plantamajoside modulates immune dysregulation and hepatic lipid metabolism in rats with nonalcoholic fatty liver disease via AMPK/Nrf2 elevation. The Kaohsiung Journal of Medical Sciences. 2023 Aug;39(8):801-10.
23. Ye J, Zheng J, Tian X, Xu B, Yuan F, Wang B, Yang Z, Huang F. Fucoxanthin attenuates free fatty acid-induced nonalcoholic fatty liver disease by regulating lipid metabolism/oxidative stress/inflammation via the AMPK/Nrf2/TLR4 signaling pathway. Marine drugs. 2022 Mar 25;20(4):225.
24. Shen B, Wang Y, Cheng J, Peng Y, Zhang Q, Li Z, Zhao L, Deng X, Feng H. Pterostilbene alleviated NAFLD via AMPK/mTOR signaling pathways and autophagy by promoting Nrf2. Phytomedicine. 2023 Jan 1;109:154561.
25. Li Y, Liu J, Ye B, Cui Y, Geng R, Liu S, Zhang Y, Guo W, Fu S. Astaxanthin alleviates nonalcoholic fatty liver disease by regulating the intestinal flora and targeting the AMPK/Nrf2 signal axis. Journal of Agricultural and Food Chemistry. 2022 Aug 16;70(34):10620-34.
26. Wang Z, Zuo J, Zhang L, Zhang Z, Wei Y. Plantamajoside promotes metformin-induced apoptosis, autophagy and proliferation arrest of liver cancer cells via suppressing Akt/GSK3β signaling. Human & Experimental Toxicology. 2022 Jan 6;41:09603271221078868.
27. Corina D, Bojin F, Ambrus R, Muntean D, Soica C, Paunescu V, Cristea M, Pinzaru I, Dehelean C. Physico-chemical and biological evaluation of flavonols: Fisetin, quercetin and kaempferol alone and incorporated in beta cyclodextrins. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2017 Apr 1;17(4):615-26.
28. BinMowyna MN, AlFaris NA. Kaempferol suppresses acetaminophen-induced liver damage by upregulation/activation of SIRT1. Pharmaceutical Biology. 2021 Jan 1;59(1):144-54.
29. Xiao X, Hu Q, Deng X, Shi K, Zhang W, Jiang Y, Ma X, Zeng J, Wang X. Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases. Pharmacological Research. 2022 Jan 1;175:106005.
30. Yang Y, Chen Z, Zhao X, Xie H, Du L, Gao H, Xie C. Mechanisms of Kaempferol in the treatment of diabetes: A comprehensive and latest review. Frontiers in endocrinology. 2022 Sep 7;13:990299.
31. Tie F, Ding J, Hu N, Dong Q, Chen Z, Wang H. Kaempferol and kaempferide attenuate oleic acid-induced lipid accumulation and oxidative stress in HepG2 cells. International journal of molecular sciences. 2021 Aug 17;22(16):8847.
32. Li N, Yin L, Shang J, Liang M, Liu Z, Yang H, Qiang G, Du G, Yang X. Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway. Biomedicine & Pharmacotherapy. 2023 Sep 1;165:115113.
33. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016 Aug 1;65(8):1038-48.
34. Karkucinska‐Wieckowska A, Simoes IC, Kalinowski P, Lebiedzinska‐Arciszewska M, Zieniewicz K, Milkiewicz P, Górska‐Ponikowska M, Pinton P, Malik AN, Krawczyk M, Oliveira PJ. Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship. European journal of clinical investigation. 2022 Mar;52(3):e13622.
35. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cellular and molecular life sciences. 2018 Sep;75(18):3313-27.
36. Ruderman NB, Julia Xu X, Nelson L, Cacicedo JM, Saha AK, Lan F, Ido Y. AMPK and SIRT1: a long-standing partnership?. American Journal of Physiology-Endocrinology and Metabolism. 2010 Apr;298(4):E751-60.
37. Long JK, Dai W, Zheng YW, Zhao SP. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Molecular Medicine. 2019 Dec;25(1):26.
38. Zhu W, Chen S, Li Z, Zhao X, Li W, Sun Y, Zhang Z, Ling W, Feng X. Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice. Nutrition & metabolism. 2014 Aug 12;11(1):35.
39. Ding S, Jiang J, Zhang G, Bu Y, Zhang G, Zhao X. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. PloS one. 2017 Aug 17;12(8):e0183541.
40. Wang CM, Yuan RS, Zhuang WY, Sun JH, Wu JY, Li H, Chen JG. Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice. Lipids in Health and Disease. 2016 Nov 16;15(1):195.
41. Kim YH, Kim DH, Lim H, Baek DY, Shin HK, Kim JK. The anti-inflammatory effects of methylsulfonylmethane on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biological and Pharmaceutical Bulletin. 2009 Apr 1;32(4):651-6.
42. Nakhostin-Roohi B, Barmaki S, Khoshkhahesh F, Bohlooli S. Effect of chronic supplementation with methylsulfonylmethane on oxidative stress following acute exercise in untrained healthy men. Journal of Pharmacy and Pharmacology. 2011 Oct;63(10):1290-4.
43. Ahn H, Kim J, Lee MJ, Kim YJ, Cho YW, Lee GS. Methylsulfonylmethane inhibits NLRP3 inflammasome activation. Cytokine. 2015 Feb 1;71(2):223-31.
44. Miller L, Thompson K, Pavlenco C, Mettu VS, Haverkamp H, Skaufel S, Basit A, Prasad B, Larsen J. The effect of daily methylsulfonylmethane (MSM) consumption on high-density lipoprotein cholesterol in healthy overweight and obese adults: a randomized controlled trial. Nutrients. 2021 Oct 15;13(10):3620.
45. Han D, Kim D, Kim H, Lee J, Lyu J, Kim JS, Shin J, Kim JS, Kim DK, Park HW. Methylsulfonylmethane ameliorates metabolic-associated fatty liver disease by restoring autophagy flux via AMPK/mTOR/ULK1 signaling pathway. Frontiers in Pharmacology. 2023 Nov 30;14:1302227.
46. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. New England Journal of Medicine. 2013 Feb 14;368(7):651-62.
47. Park HW, Park H, Semple IA, Jang I, Ro SH, Kim M, Cazares VA, Stuenkel EL, Kim JJ, Kim JS, Lee JH. Pharmacological correction of obesity-induced autophagy arrest using calcium channel blockers. Nature communications. 2014 Sep 5;5(1):4834.
48. Li Q, Tan JX, He Y, Bai F, Li SW, Hou YW, Ji LS, Gao YT, Zhang X, Zhou ZH, Yu Z. Atractylenolide III ameliorates non-alcoholic fatty liver disease by activating hepatic adiponectin receptor 1-mediated AMPK pathway. International journal of biological sciences. 2022 Jan 31;18(4):1594.
49. Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 2005 Jan 1;128(1):138-46.
50. Schimmack G, DeFronzo RA, Musi N. AMP‐activated protein kinase: role in metabolism and therapeutic implications. Diabetes, Obesity and Metabolism. 2006 Nov;8(6):591-602.